Phenylbutazone (Butazolidin)

A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.

Also Known As:

Networked: 1097 relevant articles (28 outcomes, 71 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Bachar, Sitesh C: 3 articles (07/2010 - 07/2008)
2.	Bachar, Sitesh Chandra: 2 articles (09/2012 - 10/2005)
3.	Nahar, Lutfun: 2 articles (09/2012 - 07/2010)
4.	Kundu, Joydeb Kumar: 2 articles (09/2012 - 10/2005)
5.	Nieto, Jorge E: 2 articles (01/2012 - 08/2011)
6.	Aleman, Monica: 2 articles (01/2012 - 08/2011)
7.	Foreman, J H: 2 articles (11/2011 - 02/2008)
8.	Datta, Bidyut K: 2 articles (07/2010 - 07/2008)
9.	Maciążek-Jurczyk, Małgorzata: 1 article (10/2014)
10.	van Loon, J P A M: 1 article (07/2014)

Related Diseases

1.	Inflammation 07/01/2014 - "Although phenylbutazone (PBZ) is commonly used in equine orthopaedic practice, little is known about its in vivo effects on joint inflammation and cartilage turnover. " 01/01/2008 - "Compounds 3f and 3i were found to be most active compound of this series, which shows 46.42% and 50% inflammation inhibitory activity, whereas standard drug phenylbutazone exhibit 53.57% antiinflammatory activity at a dose of 50 mg/kg po." 08/01/2002 - "Compounds 7b and 6'b were found to be potent member of this series, which showed 50.66 and 47.56%, respectively, inflammation inhibitory activity at a dose of 50 mg kg(-1) p.o., while standard drug, phenylbutazone, exhibited 45.52% anti-inflammatory activity at the same dose. " 12/01/1996 - "The effect of inflammation on the disposition of phenylbutazone (PBZ) was investigated in Thoroughbred horses. " 12/01/1996 - "The effect of inflammation on the disposition of phenylbutazone in thoroughbred horses."
2.	Pain (Aches) 07/15/2005 - "Phenylbutazone administered PO did not effectively alleviate signs of thoracolumbar pain in horses in this study." 03/01/2011 - "In the XX century, nonsteroidal anti-inflammatory drugs were synthesized, such as phenylbutazone, which was initially considered primarily a pain medication. " 02/01/2008 - "The objective was to test the hypothesis that phenylbutazone (PBZ) alleviates lameness in an adjustable heart bar shoe model of equine foot pain. " 01/01/1989 - "With phenylbutazone the post-operative swelling was not significantly reduced compared to placebo, but there was less pain and limping. " 03/01/1987 - "All ponies were given phenylbutazone orally for relief of ocular pain. "
3.	Body Weight (Weight, Body) 01/01/1997 - "Because serum concentration of phenylbutazone after single i.v. bolus administration (4.4 mg/kg of body weight) decreases more rapidly in donkeys, compared with horses, phenylbutazone may require more frequent administration in donkeys to achieve therapeutic efficacy." 12/01/1998 - "Milk clearance of phenylbutazone was 0.009 mL/h/kg body weight, or about 0.34% of total body clearance. " 01/01/2011 - "All these effects were compared with reference drug phenylbutazone (100 mg/kg body weight)." 07/01/2010 - "Maximum inhibition by the extract was observed at 250 mg/kg body weight after three hours of ingestion, which was comparable to that of the standard drug phenylbutazone at a dose of 100 mg/kg body weight. " 02/28/2008 - "From the nine fractions (A-I) obtained, of an initial chromatographic separation, fractions A and E (doses equivalents to 1.50 g dry plant/kg body weight) showed the strongest anti-inflammatory activity comparable to that of the reference drug phenylbutazone (80 mg/kg). "
4.	Ulcer 05/01/1982 - "Fr.L showed significant activity in preventing ulcer formation and gastric juice secretion in pylorus-ligated rats, and was also effective in reducing index of the phenylbutazone-induced ulcer." 01/01/1956 - "[Hepatorenal lesions in the course of experimental ulcers caused by phenylbutazone in dogs; observations on the protective effects of gastrointestinal extracts]." 03/01/1982 - "[Studies on gastric mucosal prostaglandin in phenylbutazone ulcer rats (author's transl)]." 11/01/1966 - "[Variations in the histaminopexic power of serum in ulcers induced by butazolidin (experimental study)]." 04/01/1982 - "Phenylbutazone caused exacerbation by the administration for 5 days at the middle stage of the ulcer healing process. "
5.	Edema 01/01/2013 - "The test compounds 1 and 2 displayed significant inhibitory activity at a dose of 1 mg/ear on edema formation at all determination times, with similar intensity as phenylbutazone." 11/01/1999 - "Percentage inhibition of edema by butanolic extract (33.05, P < 0.001) is comparable to that of phenylbutazone, 100 mg/kg inhibition (38.83%). " 11/01/1986 - "The compounds were generally only 1/2 to 3 times as potent as phenylbutazone in the rat paw edema antiinflammatory assay. " 01/01/1982 - "Percent inhibition of the paw edema volume by phenylbutazone (50 mg/kg p. " 01/01/1975 - "These compounds were three to five times more active than phenylbutazone as assessed from ED30 values determined on rat paw edema 5 hr after single oral doses."

Related Drugs and Biologics

1.	Indomethacin (Indometacin)
2.	Aspirin (Acetylsalicylic Acid)
3.	Dexamethasone (Maxidex)
4.	Piroxicam (Feldene)
5.	Cyproheptadine (Periactin)
6.	Naproxen (Naprosyn)
7.	Ibuprofen (Motrin)
8.	Aminopyrine (Aminophenazone)
9.	isoxicam (Vectren)
10.	droxicam

Related Therapies and Procedures

1.	Oral Administration
2.	Ligation
3.	Vagotomy
4.	Injections
5.	Aftercare (After-Treatment)